MedTrace Logo

Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Chinese Healthy Volunteers

NCT02781753 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2017-05-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the dosages of recombinant human serum albumin/interferon alpha2b fusion protein injection in healthy subjects.

Conditions

  • Healthy

Interventions

BIOLOGICAL

Human Serum Albumin/interferon alpha2b

Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C. at Day0

BIOLOGICAL

Peginterferon 180 μg single dose S.C.

Pegasys 180 mcg S.C. single dose on Day 0

Sponsors & Collaborators

  • Tianjin SinoBiotech Ltd.

    lead INDUSTRY

Principal Investigators

  • Meixia Wang, Professor · Beijing YouAn Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-07
Primary Completion
2016-08-02
Completion
2017-04-12

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02781753 on ClinicalTrials.gov